993 related articles for article (PubMed ID: 17205957)
1. Specific changes in plasma concentrations of matrix metalloproteinase-2 and -9, TIMP-1 and TGF-beta1 in patients with distinct types of primary glomerulonephritis.
Bauvois B; Mothu N; Nguyen J; Nguyen-Khoa T; Nöel LH; Jungers P
Nephrol Dial Transplant; 2007 Apr; 22(4):1115-22. PubMed ID: 17205957
[TBL] [Abstract][Full Text] [Related]
2. Plasma transforming growth factor beta1, metalloproteinase-1 and tissue inhibitor of metalloproteinases-1 in acute viral hepatitis type B.
Flisiak R; Jaroszewicz J; Lapiński TW; Flisiak I; Rogalska M; Prokopowicz D
Regul Pept; 2005 Nov; 131(1-3):54-8. PubMed ID: 16081167
[TBL] [Abstract][Full Text] [Related]
3. Matrix-Metallo-Proteinases and their tissue inhibitors in radiation-induced lung injury.
Yang K; Palm J; König J; Seeland U; Rosenkranz S; Feiden W; Rübe C; Rübe CE
Int J Radiat Biol; 2007 Oct; 83(10):665-76. PubMed ID: 17729161
[TBL] [Abstract][Full Text] [Related]
4. Expression of matrix metalloproteinase-2 and -9 and their inhibitors, tissue inhibitor of metalloproteinase-1 and -2, in primary cultures of human prostatic stromal and epithelial cells.
Wilson MJ; Sellers RG; Wiehr C; Melamud O; Pei D; Peehl DM
J Cell Physiol; 2002 May; 191(2):208-16. PubMed ID: 12064464
[TBL] [Abstract][Full Text] [Related]
5. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury.
Kuyvenhoven JP; Molenaar IQ; Verspaget HW; Veldman MG; Palareti G; Legnani C; Moolenburgh SE; Terpstra OT; Lamers CB; van Hoek B; Porte RJ
Thromb Haemost; 2004 Mar; 91(3):506-13. PubMed ID: 14983226
[TBL] [Abstract][Full Text] [Related]
6. Changes in levels of matrix metalloproteinase-2 and -9, pregnancy-associated plasma protein-A in patients with various nephropathies.
Zakiyanov O; Kalousová M; Kratochvilová M; Kríha V; Zima T; Tesar V
J Nephrol; 2013; 26(3):502-9. PubMed ID: 22760877
[TBL] [Abstract][Full Text] [Related]
7. [Influence of recombinant transforming growth factor-beta3 on collagen synthesis and deposition: experiment with rat cell model of liver fibrosis].
Li Q; Zhou X; Yu J; Qian W; Xu KS
Zhonghua Yi Xue Za Zhi; 2008 May; 88(18):1273-8. PubMed ID: 18844103
[TBL] [Abstract][Full Text] [Related]
8. An imbalance between matrix metalloproteinase-2 and tissue inhibitor of matrix metalloproteinase-2 contributes to the development of early diabetic nephropathy.
Han SY; Jee YH; Han KH; Kang YS; Kim HK; Han JY; Kim YS; Cha DR
Nephrol Dial Transplant; 2006 Sep; 21(9):2406-16. PubMed ID: 16728425
[TBL] [Abstract][Full Text] [Related]
9. Role of platelet-derived growth factor and transforming growth factor beta1 the in the regulation of metalloproteinase expressions.
Borrelli V; di Marzo L; Sapienza P; Colasanti M; Moroni E; Cavallaro A
Surgery; 2006 Sep; 140(3):454-63. PubMed ID: 16934609
[TBL] [Abstract][Full Text] [Related]
10. Renal expression of matrix metalloproteinases in human ANCA-associated glomerulonephritis.
Sanders JS; van Goor H; Hanemaaijer R; Kallenberg CG; Stegeman CA
Nephrol Dial Transplant; 2004 Jun; 19(6):1412-9. PubMed ID: 15034162
[TBL] [Abstract][Full Text] [Related]
11. Downregulation of vascular matrix metalloproteinase inducer and activator proteins in hypertensive patients.
Ergul A; Portik-Dobos V; Hutchinson J; Franco J; Anstadt MP
Am J Hypertens; 2004 Sep; 17(9):775-82. PubMed ID: 15363819
[TBL] [Abstract][Full Text] [Related]
12. [Significance of imbalance between matrix metalloproteinases and tissue type inhibitor of metalloproteinases in renal tubulointerstitial lesions of aging rats].
Chen RQ; Chen XM; Cui SW; Cai GY; Shi SZ; Xie YS; Lu Y; Peng LX
Zhonghua Yi Xue Za Zhi; 2004 Jun; 84(11):937-42. PubMed ID: 15329283
[TBL] [Abstract][Full Text] [Related]
13. Keloid-derived fibroblasts show increased secretion of factors involved in collagen turnover and depend on matrix metalloproteinase for migration.
Fujiwara M; Muragaki Y; Ooshima A
Br J Dermatol; 2005 Aug; 153(2):295-300. PubMed ID: 16086739
[TBL] [Abstract][Full Text] [Related]
14. Expression and response to angiotensin-converting enzyme inhibition of matrix metalloproteinases 2 and 9 in renal glomerular damage in young transgenic rats with renin-dependent hypertension.
Bolbrinker J; Markovic S; Wehland M; Melenhorst WB; van Goor H; Kreutz R
J Pharmacol Exp Ther; 2006 Jan; 316(1):8-16. PubMed ID: 16166267
[TBL] [Abstract][Full Text] [Related]
15. Circulating matrix metalloproteinase-8 (MMP-8) and MMP-9 are increased in chronic periodontal disease and decrease after non-surgical periodontal therapy.
Marcaccini AM; Novaes AB; Meschiari CA; Souza SL; Palioto DB; Sorgi CA; Faccioli LH; Tanus-Santos JE; Gerlach RF
Clin Chim Acta; 2009 Nov; 409(1-2):117-22. PubMed ID: 19751716
[TBL] [Abstract][Full Text] [Related]
16. Increased circulating levels of matrix metalloproteinase (MMP)-8, MMP-9, and pro-inflammatory markers in patients with metabolic syndrome.
Gonçalves FM; Jacob-Ferreira AL; Gomes VA; Casella-Filho A; Chagas AC; Marcaccini AM; Gerlach RF; Tanus-Santos JE
Clin Chim Acta; 2009 May; 403(1-2):173-7. PubMed ID: 19254704
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of matrix metalloproteinase on hepatic transforming growth factor beta1 and caspase-3 activation in hemorrhage.
Maitra SR; Bhaduri S; El-Maghrabi MR; Shapiro MJ
Acad Emerg Med; 2005 Sep; 12(9):797-803. PubMed ID: 16141011
[TBL] [Abstract][Full Text] [Related]
18. Serum matrix metalloproteinases MMP-2 and MMP-9 and metalloproteinase tissue inhibitors TIMP-1 and TIMP-2 in diabetic nephropathy.
Rysz J; Banach M; Stolarek RA; Pasnik J; Cialkowska-Rysz A; Koktysz R; Piechota M; Baj Z
J Nephrol; 2007; 20(4):444-52. PubMed ID: 17879211
[TBL] [Abstract][Full Text] [Related]
19. Serum TIMP-1, TIMP-2, and MMP-1 in patients with systemic sclerosis, primary Raynaud's phenomenon, and in normal controls.
Young-Min SA; Beeton C; Laughton R; Plumpton T; Bartram S; Murphy G; Black C; Cawston TE
Ann Rheum Dis; 2001 Sep; 60(9):846-51. PubMed ID: 11502611
[TBL] [Abstract][Full Text] [Related]
20. [Transforming growth factor beta, metalloproteinase 2 and its tissue inhibitor 2 in the serum from patients with early and late boreliosis].
Pancewicz SA; Izycka A; Klibingat M; Zajkowska JM; Swierzbińska-Pijanowska R; Kondrusik M; Grygorczuk SS; Izycki T; Hermanowska-Szpakowicz T
Pol Merkur Lekarski; 2008 Dec; 25(150):495-9. PubMed ID: 19205380
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
